| 患者特征 | 单纯药物治疗 | Z/c2 | P1 | 透析 + RASI治疗 | Z/c2 | P2 | ||
| 使用RASI n = 137 | 未用RASI n = 35 | 腹膜透析 n = 6 | 血液透析 n = 4 | |||||
| 年龄(年)，n (%) |
|
| 5.389 | 0.123 |
|
| 4.551 | 0.143 |
| <30 | 12 (8.8) | 3 (9.4) |
|
| 4 (66.7) | 0 |
|
|
| 30~50 | 104 (76.0) | 22 (62.5) |
|
| 1 (16.7) | 3 (75.0) |
|
|
| 51~70 | 17 (12.4) | 10 (28.1) |
|
| 0 | 0 |
|
|
| ≥71 | 4 (3.0) | 0 |
|
| 1 (16.7) | 1 (25.0) |
|
|
| 性别n (%) |
|
| 0.119 | 0.835 |
|
| - | 0.500 |
| 男，n (%) | 98 (71.5) | 24 (68.6) |
|
| 5 (83.3) | 2 (50.0) |
|
|
| 眼底病变 |
|
| 7.279 | 0.087 |
|
| 1.425 | 0.743 |
| 视网膜出血渗出 | 64 (46.7) | 11 (31.4) |
|
| 3 (50) | 1 (25) |
|
|
| 棉絮斑 | 23 (16.8) | 4 (11.4) |
|
| 0 | 0 |
|
|
| 视乳头水肿 | 13 (9.5) | 2 (1.5) |
|
| 1 (16.7) | 2 (50) |
|
|
| 无眼底表现 | 37 (0.3) | 18 (0.5) |
|
| 2 (0.3) | 1 (25) |
|
|
| LVEF (%), n (%) |
|
| 2.166 | 0.553 |
|
| - | 0.400 |
| <40 | 7 (5.1) | 0 |
|
| 0 | 0 |
|
|
| 40~49 | 19 (13.9) | 3 (8.6) |
|
| 0 | 1 (25.0) |
|
|
| ≥50 | 99 (72.3) | 29 (82.9) |
|
| 6 (100) | 3 (75.0) |
|
|
| 缺失 | 12 (8.8) | 3 (8.6) |
|
| 0 | 0 |
|
|
| 继发性TMA | 5 (3.6) | 0 | - | - | 1 (16.7) | 1 (25.0) | - | - |
| SBP (mmHg) | 222 ± 23.72 | 210 ± 26.48 | −2.77 | 0.006 | 220 ± 18.97 | 209 ± 19.21 | −1.20 | 0.230 |
| DBP (mmHg) | 140 ± 20.93 | 133 ± 18.71 | −1.81 | 0.071 | 157 ± 20.46 | 130 ± 34.07 | −1.18 | 0.237 |
| eGFR (ml/min/1.73 m2) | 33.79 ± 25.30 | 25.20 ± 22.99 | −2.25 | 0.025 | 4.95 ± 1.37 | 9.41 ± 4.00 | −1.92 | 0.055 |
| 肌酐(μmol/L) | 280.54 ± 169.65 | 342.85 ± 162.27 | −2.21 | 0.027 | 1133.43 ± 311.68 | 654.30 ± 380.25 | −1.49 | 0.136 |
| 尿素(mmol/L) | 13.55 ± 6.91 | 16.38 ± 7.62 | −2.15 | 0.031 | 36.69 ± 8.86 | 24.46 ± 6.73 | −1.92 | 0.055 |
| 24小时尿蛋白(g/24h) | 2.34 ± 2.58 | 3.39 ± 2.79 | −2.13 | 0.033 | 0.96 ± 0.46 | 0.77 ± 0.18 | −0.46 | 0.643 |